Key result
The purinergic system, including P1 and P2 receptors and enzymes like CD39, CD73, and ADA, plays a central role in the physiopathology of diabetes and hypertension.
Why the study?
Knowledge regarding the role of the purinergic system in individuals with diabetes mellitus and hypertension remains restricted.
The purinergic signaling axis is centrally involved in the pathophysiology of diabetes and hypertension, representing a potential target for therapeutic intervention.
Answers are grounded in this paper and cite their sources.
May inform future therapies targeting purinergic pathways in diabetes and hypertension; leaves open confirmation in prospective trials.
Diabetes mellitus (DM) and hypertension are highly prevalent worldwide health problems and frequently associated with severe clinical complications, such as diabetic cardiomyopathy, nephropathy, retinopathy, neuropathy, stroke, and cardiac arrhythmia, among others. Despite all existing research results and reasonable speculations, knowledge about the role of purinergic system in individuals with DM and hypertension remains restricted. Purinergic signaling accounts for a complex network of receptors and extracellular enzymes responsible for the recognition and degradation of extracellular nucleotides and adenosine. The main components of this system that will be presented in this review are: P1 and P2 receptors and the enzymatic cascade composed by CD39 (NTPDase; with ATP and ADP as a substrate), CD73 (5'-nucleotidase; with AMP as a substrate), and adenosine deaminase (ADA; with adenosine as a substrate). The purinergic system has recently emerged as a central player in several physiopathological conditions, particularly those linked to inflammatory responses such as diabetes and hypertension. Therefore, the present review focuses on changes in both purinergic P1 and P2 receptor expression as well as the activities of CD39, CD73, and ADA in diabetes and hypertension conditions. It can be postulated that the manipulation of the purinergic axis at different levels can prevent or exacerbate the insurgency and evolution of diabetes and hypertension working as a compensatory mechanism.
No takes yet. Share an insight, caveat, or question.
Reichert et al. (2021) conducted a review in Diabetes and hypertension. Purinergic signaling was evaluated. The purinergic system, including P1 and P2 receptors and enzymes like CD39, CD73, and ADA, plays a central role in the physiopathology of diabetes and hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: